Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is...
14 insider purchases on record · latest filing 2024-11-18.
Insiders have also filed 78 sale transactions at TNGX.